Translational Drug Development

Translational Drug Development, commonly branded as TD2 or TD2 Oncology, is a United States-based contract research organization (CRO) dedicated to oncology drug development. Headquartered in Scottsdale, Arizona, the company positions itself as a precision oncology partner that helps biopharmaceutical sponsors move cancer therapies from preclinical discovery through clinical trials and regulatory submission. Its service model spans the full development continuum, combining translational science, preclinical model systems, bioanalytical and flow cytometry laboratories, regulatory strategy, and clinical trial execution. On the clinical side, TD2 offers study design and protocol development, patient identification and site engagement, site management and monitoring, strategic third-party vendor management, biostatistics, data management, clinical flow cytometry, pharmacovigilance, medical monitoring, electronic trial master file (eTMF) management, and quality assurance. These capabilities are organized around therapeutic areas in which the company specializes, including radiopharmaceuticals, hematologic malignancies, antibody-drug conjugates (ADCs), small molecules, and cancer vaccine development. TD2's preclinical and translational offering includes a broad portfolio of model systems such as syngeneic tumor models, orthotopic tumor models, patient-derived xenograft (PDX) models, humanized mouse models, adoptive cell therapy models, cell line-derived xenograft (CDX) models, and a diet-induced obesity tumor model. Supporting these are bioanalytical services including preclinical flow cytometry, metabolomics and proteomics analysis, DMPK/ADME services, in vivo and in vitro characterization, in vivo optical imaging, therapeutic evaluation, and antibody-drug conjugate (ADC) flow cytometry. The company also provides regulatory support through translational regulatory services, regulatory and medical writing, expert panel discussions, submission and specialty filing, and gap analysis and roadmap development. As a private company, TD2 does not publicly report financial results in the manner of a listed corporation. Its brand identity centers on the concept of "precision oncology" and on accelerating oncology innovation through translational expertise. The company maintains an active news and events presence, including partnership announcements such as a collaboration with Minerva Imaging to expand radiopharmaceutical development support. TD2 serves sponsors ranging from emerging biotech companies to larger pharmaceutical organizations seeking specialized oncology development capabilities.

Translational Drug Development, known by the brand TD2 or TD2 Oncology, is a United States-based contract research organization headquartered in Scottsdale, Arizona. The company was established to serve the specialized needs of oncology drug developers, an area of pharmaceutical research that demands integrated translational science, preclinical modeling, and clinical trial execution. Its name reflects its core proposition: bridging the "translational" gap between laboratory discovery and clinical application. TD2 built its identity around precision oncology, assembling a service portfolio that spans the development continuum. On the preclinical and translational side, the company developed a broad menu of model systems — syngeneic, orthotopic, patient-derived xenograft (PDX), humanized mouse, adoptive cell therapy, and cell line-derived xenograft (CDX) models — alongside bioanalytical capabilities such as preclinical and clinical flow cytometry, metabolomics and proteomics, DMPK/ADME, in vivo optical imaging, and antibody-drug conjugate (ADC) flow cytometry. These capabilities support therapeutic areas including radiopharmaceuticals, hematologic malignancies, antibody-drug conjugates, small molecules, and cancer vaccines. On the clinical and regulatory side, TD2 expanded into full-service clinical trial support: study design and protocol development, patient identification and site engagement, site management and monitoring, strategic third-party vendor management, biostatistics, data management, pharmacovigilance, medical monitoring, eTMF management, and quality assurance. The company also offers translational regulatory services, regulatory and medical writing, expert panel discussions, submission and specialty filing, and gap analysis and roadmap development. As a private company, TD2 does not disclose financial results publicly. It maintains an active communications program through press releases, news, events, and a blog, and it pursues partnerships to broaden its capabilities — for example, a July 2026 partnership with Minerva Imaging aimed at expanding radiopharmaceutical development support. The company continues to position itself as a specialist partner for biopharmaceutical sponsors seeking to accelerate oncology programs from discovery through approval.

• TD2 Oncology announced a partnership with Minerva Imaging to expand radiopharmaceutical development support.

Precision oncology CRO accelerating oncology drug development through translational expertise and integrated preclinical-to-clinical services.

• Clinical Trial Services

  Study design and protocol development, patient identification and site engagement, site management and monitoring, strategic third-party vendor management, biostatistics, data management, clinical flow cytometry, pharmacovigilance, medical monitoring, eTMF management, and quality assurance.

• Preclinical Model Systems

  Syngeneic tumor models, orthotopic tumor models, patient-derived xenograft (PDX) models, humanized mouse models, diet-induced obesity tumor model, adoptive cell therapy models, and cell line-derived xenograft (CDX) models.

• Bioanalytical Services

  Preclinical flow cytometry, metabolomics and proteomics analysis, DMPK/ADME services, in vivo and in vitro characterization, in vivo optical imaging, therapeutic evaluation, and antibody-drug conjugate (ADC) flow cytometry.

• Regulatory Support

  Translational regulatory services, full program management and consulting, protocol design, program budget and timeline, executive plan, trial enablement, regulatory and medical writing, expert panel discussions, submission and specialty filing, and gap analysis and roadmap development.

• Flow Cytometry Analysis Services

  Preclinical flow cytometry, clinical flow cytometry, and related clinical study management and regulatory support.

1. 1TD2 Oncology | Your Oncology CRO Partnertd2inc.com
2. 2About TD2 - TD2 Precision Oncologytd2inc.com
3. 3eTMF Management Services - TD2 Precision Oncologytd2inc.com
4. 4Translational Drug Development (United States) - Wikidatawikidata.org